Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 171-180 of 664 for Cancer

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study To Investigate The Safety And Efficacy Of KQB365 As Monotherapy And In Combination In Participants With Advanced Solid Malignancies

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Phase 2 Trial Of Voyager V1 In Combination With Cemiplimab In Cancer Patients

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. A Study Of Tucatinib With Trastuzumab And MFOLFOX6 Versus Standard Of Care Treatment In First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. A Master Protocol To Evaluate The Long-Term Safety Of (LY3527727) Pirtobrutinib

    Rochester, MN

  5. A Study Of Movement And Memory After Breast Cancer

    Scottsdale/Phoenix, AZ

  6. Testing Teclistamab (TECVAYLI) In Combination With Iberdomide For Hard-to-Treat Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. Targeted Alpha-Particle Therapy For Advanced SSTR2 Positive Neuroendocrine Tumors

    Jacksonville, FL, Rochester, MN

  8. Radioembolization With Tremelimumab And Durvalumab For Locally Advanced Unresectable Or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

    Jacksonville, FL

  9. A Phase I/II Study To Evaluate AZD5851 In GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Sacituzumab Tirumotecan (MK-2870) In Combination With Pembrolizumab Versus Pembrolizumab Alone In Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer